BCL2 and hepatocellular carcinoma: Etomoxir was also able to increase the sensitivity of hepatocellular carcinoma (HCC) CSCs to sorafenib [88] and showed synergy with ABT-737, a molecule targeting BCL-2, in the context of acute myeloid leukemia (AML) [168].